Last 12 months
Inside the activity.
3 purchase rows · 2 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 3 | 1 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 28, 2019 Filed Mar 2, 2019 00:37 UTC |
Lewis-Hall Freda CExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 45,634 | $0.00 Strike: $43.35 | $0.00 |
DisclosureSEC source: 0001225208-19-004215 · doc4.xml · derivative · entry 9 Lewis-Hall Freda C · CIK 0001437909 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,634 Underlying: Common Stock · 45,634 shares Expires 2026-02-28 F8 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F8 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 28, 2019 Filed Mar 2, 2019 00:37 UTC |
Lewis-Hall Freda CExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 54,151 | $0.00 Strike: $43.35 | $0.00 |
DisclosureSEC source: 0001225208-19-004215 · doc4.xml · derivative · entry 8 Lewis-Hall Freda C · CIK 0001437909 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,151 Underlying: Common Stock · 54,151 shares Expires 2024-02-28 F7 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F7 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 28, 2019 Filed Mar 2, 2019 00:37 UTC |
MACKENZIE ALEXANDER RExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 60,846 | $0.00 Strike: $43.35 | $0.00 |
DisclosureSEC source: 0001225208-19-004216 · doc4.xml · derivative · entry 5 MACKENZIE ALEXANDER R · CIK 0001678459 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,846 Underlying: Common Stock · 60,846 shares Expires 2026-02-28 F4 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F4 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 28, 2019 Filed Mar 2, 2019 00:37 UTC |
MACKENZIE ALEXANDER RExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 72,201 | $0.00 Strike: $43.35 | $0.00 |
DisclosureSEC source: 0001225208-19-004216 · doc4.xml · derivative · entry 4 MACKENZIE ALEXANDER R · CIK 0001678459 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,201 Underlying: Common Stock · 72,201 shares Expires 2024-02-28 F3 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F3 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 28, 2019 Filed Mar 2, 2019 00:47 UTC |
ROGERS DAWNExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 41,071 | $0.00 Strike: $43.35 | $0.00 |
DisclosureSEC source: 0001225208-19-004217 · doc4.xml · derivative · entry 8 ROGERS DAWN · CIK 0001742308 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,071 Underlying: Common Stock · 41,071 shares Expires 2026-02-28 F7 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F7 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 28, 2019 Filed Mar 2, 2019 00:47 UTC |
ROGERS DAWNExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 48,736 | $0.00 Strike: $43.35 | $0.00 |
DisclosureSEC source: 0001225208-19-004217 · doc4.xml · derivative · entry 7 ROGERS DAWN · CIK 0001742308 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,736 Underlying: Common Stock · 48,736 shares Expires 2024-02-28 F6 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F6 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 28, 2019 Filed Mar 2, 2019 00:47 UTC |
READ IAN CDirector · Executive Chairman
|
GrantStock Appreciation Rights · Derivative | 202,819 | $0.00 Strike: $43.35 | $0.00 |
DisclosureSEC source: 0001225208-19-004218 · doc4.xml · derivative · entry 6 READ IAN C · CIK 0001372915 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 202,819 Underlying: Common Stock · 202,819 shares Expires 2026-02-28 F5 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F5 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 28, 2019 Filed Mar 2, 2019 00:47 UTC |
READ IAN CDirector · Executive Chairman
|
GrantStock Appreciation Rights · Derivative | 240,670 | $0.00 Strike: $43.35 | $0.00 |
DisclosureSEC source: 0001225208-19-004218 · doc4.xml · derivative · entry 5 READ IAN C · CIK 0001372915 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,670 Underlying: Common Stock · 240,670 shares Expires 2024-02-28 F4 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F4 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 28, 2019 Filed Mar 2, 2019 00:47 UTC |
SUSMAN SALLYExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 73,521 | $0.00 Strike: $43.35 | $0.00 |
DisclosureSEC source: 0001225208-19-004219 · doc4.xml · derivative · entry 9 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,521 Underlying: Common Stock · 73,521 shares Expires 2026-02-28 F8 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F8 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 28, 2019 Filed Mar 2, 2019 00:47 UTC |
SUSMAN SALLYExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 87,243 | $0.00 Strike: $43.35 | $0.00 |
DisclosureSEC source: 0001225208-19-004219 · doc4.xml · derivative · entry 8 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,243 Underlying: Common Stock · 87,243 shares Expires 2024-02-28 F7 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F7 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 28, 2019 Filed Mar 2, 2019 00:47 UTC |
YOUNG JOHN DGroup President
|
GrantStock Appreciation Rights · Derivative | 101,409 | $0.00 Strike: $43.35 | $0.00 |
DisclosureSEC source: 0001225208-19-004220 · doc4.xml · derivative · entry 10 YOUNG JOHN D · CIK 0001551792 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,409 Underlying: Common Stock · 101,409 shares Expires 2026-02-28 F8 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F8 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 28, 2019 Filed Mar 2, 2019 00:47 UTC |
YOUNG JOHN DGroup President
|
GrantStock Appreciation Rights · Derivative | 120,335 | $0.00 Strike: $43.35 | $0.00 |
DisclosureSEC source: 0001225208-19-004220 · doc4.xml · derivative · entry 9 YOUNG JOHN D · CIK 0001551792 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,335 Underlying: Common Stock · 120,335 shares Expires 2024-02-28 F7 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F7 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 27, 2019 Filed Mar 2, 2019 00:29 UTC |
BOURLA ALBERTDirector · Chief Executive Officer
|
Exercise / conversionStock Appreciation Rights · Derivative | 64,322 | $0.00 Strike: $32.23 | $0.00 |
DisclosureSEC source: 0001225208-19-004206 · doc4.xml · derivative · entry 6 BOURLA ALBERT · CIK 0001595703 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 64,322 shares Expires 2019-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 27, 2019 Filed Mar 2, 2019 00:29 UTC |
BOURLA ALBERTDirector · Chief Executive Officer
|
Tax withholdingCommon Stock | 39,724 | $42.31 | $1,680,722.44 |
DisclosureSEC source: 0001225208-19-004206 · doc4.xml · nonDerivative · entry 4 BOURLA ALBERT · CIK 0001595703 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,212 F4 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F5 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. Read SEC document |
| February 27, 2019 Filed Mar 2, 2019 00:29 UTC |
BOURLA ALBERTDirector · Chief Executive Officer
|
Tax withholdingCommon Stock | 12,046 | $42.93 | $517,134.78 |
DisclosureSEC source: 0001225208-19-004206 · doc4.xml · nonDerivative · entry 3 BOURLA ALBERT · CIK 0001595703 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 319,936 F3 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. Read SEC document |
| February 27, 2019 Filed Mar 2, 2019 00:29 UTC |
BOURLA ALBERTDirector · Chief Executive Officer
|
Exercise / conversionCommon Stock | 64,322 | $32.23 | $2,073,098.06 |
DisclosureSEC source: 0001225208-19-004206 · doc4.xml · nonDerivative · entry 2 BOURLA ALBERT · CIK 0001595703 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 331,982 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 27, 2019 Filed Mar 2, 2019 00:29 UTC |
BOURLA ALBERTDirector · Chief Executive Officer
|
GrantCommon Stock | 96,183 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-004206 · doc4.xml · nonDerivative · entry 1 BOURLA ALBERT · CIK 0001595703 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 267,660 F1 · shares: The reported transaction constitutes the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document |
| February 27, 2019 Filed Mar 2, 2019 00:29 UTC |
CANGIALOSI LORETTA VSr. Vice President, Controller
|
Exercise / conversionStock Appreciation Rights · Derivative | 25,729 | $0.00 Strike: $32.23 | $0.00 |
DisclosureSEC source: 0001225208-19-004207 · doc4.xml · derivative · entry 8 CANGIALOSI LORETTA V · CIK 0001174449 · Sr. Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,729 shares Expires 2019-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 27, 2019 Filed Mar 2, 2019 00:29 UTC |
CANGIALOSI LORETTA VSr. Vice President, Controller
|
Tax withholdingCommon Stock | 15,890 | $42.31 | $672,305.90 |
DisclosureSEC source: 0001225208-19-004207 · doc4.xml · nonDerivative · entry 5 CANGIALOSI LORETTA V · CIK 0001174449 · Sr. Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,125 F5 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F6 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. Read SEC document |
| February 27, 2019 Filed Mar 2, 2019 00:29 UTC |
CANGIALOSI LORETTA VSr. Vice President, Controller
|
Tax withholdingCommon Stock | 4,819 | $42.93 | $206,879.67 |
DisclosureSEC source: 0001225208-19-004207 · doc4.xml · nonDerivative · entry 4 CANGIALOSI LORETTA V · CIK 0001174449 · Sr. Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,015 F4 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. Read SEC document |
| February 27, 2019 Filed Mar 2, 2019 00:29 UTC |
CANGIALOSI LORETTA VSr. Vice President, Controller
|
Tax withholdingCommon Stock | 3,926 | $42.93 | $168,543.18 |
DisclosureSEC source: 0001225208-19-004207 · doc4.xml · nonDerivative · entry 3 CANGIALOSI LORETTA V · CIK 0001174449 · Sr. Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,834 F3 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document |
| February 27, 2019 Filed Mar 2, 2019 00:29 UTC |
CANGIALOSI LORETTA VSr. Vice President, Controller
|
GrantCommon Stock | 8,017 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-004207 · doc4.xml · nonDerivative · entry 2 CANGIALOSI LORETTA V · CIK 0001174449 · Sr. Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,760 F2 · shares: The reported transaction constitutes the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document |
| February 27, 2019 Filed Mar 2, 2019 00:29 UTC |
CANGIALOSI LORETTA VSr. Vice President, Controller
|
Exercise / conversionCommon Stock | 25,729 | $32.23 | $829,245.67 |
DisclosureSEC source: 0001225208-19-004207 · doc4.xml · nonDerivative · entry 1 CANGIALOSI LORETTA V · CIK 0001174449 · Sr. Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,743 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 27, 2019 Filed Mar 2, 2019 00:29 UTC |
DAMELIO FRANK AExecutive Vice President
|
Exercise / conversionStock Appreciation Rights · Derivative | 182,247 | $0.00 Strike: $32.23 | $0.00 |
DisclosureSEC source: 0001225208-19-004208 · doc4.xml · derivative · entry 6 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 182,247 shares Expires 2019-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 27, 2019 Filed Mar 2, 2019 00:29 UTC |
DAMELIO FRANK AExecutive Vice President
|
Tax withholdingCommon Stock | 112,552 | $42.31 | $4,762,075.12 |
DisclosureSEC source: 0001225208-19-004208 · doc4.xml · nonDerivative · entry 5 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 490,576 F5 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F6 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. Read SEC document |
| February 27, 2019 Filed Mar 2, 2019 00:29 UTC |
DAMELIO FRANK AExecutive Vice President
|
Tax withholdingCommon Stock | 47,101 | $42.93 | $2,022,045.93 |
DisclosureSEC source: 0001225208-19-004208 · doc4.xml · nonDerivative · entry 4 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 603,128 F4 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document |
| February 27, 2019 Filed Mar 2, 2019 00:29 UTC |
DAMELIO FRANK AExecutive Vice President
|
Tax withholdingCommon Stock | 34,131 | $42.93 | $1,465,243.83 |
DisclosureSEC source: 0001225208-19-004208 · doc4.xml · nonDerivative · entry 3 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 650,229 F3 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. Read SEC document |
| February 27, 2019 Filed Mar 2, 2019 00:29 UTC |
DAMELIO FRANK AExecutive Vice President
|
GrantCommon Stock | 96,183 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-004208 · doc4.xml · nonDerivative · entry 2 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 684,360 F2 · shares: The reported transaction constitutes the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document |
| February 27, 2019 Filed Mar 2, 2019 00:29 UTC |
DAMELIO FRANK AExecutive Vice President
|
Exercise / conversionCommon Stock | 182,247 | $32.23 | $5,873,820.81 |
DisclosureSEC source: 0001225208-19-004208 · doc4.xml · nonDerivative · entry 1 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 588,177 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 27, 2019 Filed Mar 2, 2019 00:29 UTC |
Dolsten MikaelPresident R&D
|
Tax withholdingCommon Stock | 47,101 | $42.93 | $2,022,045.93 |
DisclosureSEC source: 0001225208-19-004210 · doc4.xml · nonDerivative · entry 3 Dolsten Mikael · CIK 0001437590 · President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 332,488 F3 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document |
| February 27, 2019 Filed Mar 2, 2019 00:29 UTC |
Dolsten MikaelPresident R&D
|
Tax withholdingCommon Stock | 26,672 | $42.93 | $1,145,028.96 |
DisclosureSEC source: 0001225208-19-004210 · doc4.xml · nonDerivative · entry 2 Dolsten Mikael · CIK 0001437590 · President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 379,589 F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the settlement of stock units from previously exercised stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 27, 2019 Filed Mar 2, 2019 00:29 UTC |
Dolsten MikaelPresident R&D
|
GrantCommon Stock | 96,183 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-004210 · doc4.xml · nonDerivative · entry 1 Dolsten Mikael · CIK 0001437590 · President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 406,261 F1 · shares: The reported transaction constitutes the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document |
| February 27, 2019 Filed Mar 2, 2019 00:37 UTC |
Hwang AngelaGroup President
|
Exercise / conversionStock Appreciation Rights · Derivative | 11,792 | $0.00 Strike: $32.23 | $0.00 |
DisclosureSEC source: 0001225208-19-004212 · doc4.xml · derivative · entry 8 Hwang Angela · CIK 0001725474 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,792 shares Expires 2019-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 27, 2019 Filed Mar 2, 2019 00:37 UTC |
Hwang AngelaGroup President
|
Tax withholdingCommon Stock | 7,283 | $42.31 | $308,143.73 |
DisclosureSEC source: 0001225208-19-004212 · doc4.xml · nonDerivative · entry 5 Hwang Angela · CIK 0001725474 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,230 F5 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F6 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. Read SEC document |
| February 27, 2019 Filed Mar 2, 2019 00:37 UTC |
Hwang AngelaGroup President
|
Tax withholdingCommon Stock | 2,270 | $42.93 | $97,451.10 |
DisclosureSEC source: 0001225208-19-004212 · doc4.xml · nonDerivative · entry 4 Hwang Angela · CIK 0001725474 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,513 F4 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document |
| February 27, 2019 Filed Mar 2, 2019 00:37 UTC |
Hwang AngelaGroup President
|
Tax withholdingCommon Stock | 1,532 | $42.93 | $65,768.76 |
DisclosureSEC source: 0001225208-19-004212 · doc4.xml · nonDerivative · entry 3 Hwang Angela · CIK 0001725474 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,783 F3 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. Read SEC document |
| February 27, 2019 Filed Mar 2, 2019 00:37 UTC |
Hwang AngelaGroup President
|
GrantCommon Stock | 6,680 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-004212 · doc4.xml · nonDerivative · entry 2 Hwang Angela · CIK 0001725474 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,315 F2 · shares: The reported transaction constitutes the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document |
| February 27, 2019 Filed Mar 2, 2019 00:37 UTC |
Hwang AngelaGroup President
|
Exercise / conversionCommon Stock | 11,792 | $32.23 | $380,056.16 |
DisclosureSEC source: 0001225208-19-004212 · doc4.xml · nonDerivative · entry 1 Hwang Angela · CIK 0001725474 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,635 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 27, 2019 Filed Mar 2, 2019 00:37 UTC |
GOETTLER MICHAELGroup President
|
Exercise / conversionStock Appreciation Rights · Derivative | 30,017 | $0.00 Strike: $32.23 | $0.00 |
DisclosureSEC source: 0001225208-19-004211 · doc4.xml · derivative · entry 6 GOETTLER MICHAEL · CIK 0001745691 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,017 shares Expires 2019-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 27, 2019 Filed Mar 2, 2019 00:37 UTC |
GOETTLER MICHAELGroup President
|
Tax withholdingCommon Stock | 18,538 | $42.31 | $784,342.78 |
DisclosureSEC source: 0001225208-19-004211 · doc4.xml · nonDerivative · entry 5 GOETTLER MICHAEL · CIK 0001745691 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,249 F5 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F6 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. Read SEC document |
| February 27, 2019 Filed Mar 2, 2019 00:37 UTC |
GOETTLER MICHAELGroup President
|
Tax withholdingCommon Stock | 5,989 | $42.93 | $257,107.77 |
DisclosureSEC source: 0001225208-19-004211 · doc4.xml · nonDerivative · entry 4 GOETTLER MICHAEL · CIK 0001745691 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,787 F4 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. Read SEC document |
| February 27, 2019 Filed Mar 2, 2019 00:37 UTC |
GOETTLER MICHAELGroup President
|
Tax withholdingCommon Stock | 3,556 | $42.93 | $152,659.08 |
DisclosureSEC source: 0001225208-19-004211 · doc4.xml · nonDerivative · entry 3 GOETTLER MICHAEL · CIK 0001745691 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,776 F3 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document |
| February 27, 2019 Filed Mar 2, 2019 00:37 UTC |
GOETTLER MICHAELGroup President
|
GrantCommon Stock | 6,680 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-004211 · doc4.xml · nonDerivative · entry 2 GOETTLER MICHAEL · CIK 0001745691 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,332 F2 · shares: The reported transaction constitutes the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document |
| February 27, 2019 Filed Mar 2, 2019 00:37 UTC |
GOETTLER MICHAELGroup President
|
Exercise / conversionCommon Stock | 30,017 | $32.23 | $967,447.91 |
DisclosureSEC source: 0001225208-19-004211 · doc4.xml · nonDerivative · entry 1 GOETTLER MICHAEL · CIK 0001745691 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,652 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 27, 2019 Filed Mar 2, 2019 00:37 UTC |
JOHNSON RADY AExecutive Vice President
|
Exercise / conversionStock Appreciation Rights · Derivative | 30,017 | $0.00 Strike: $32.23 | $0.00 |
DisclosureSEC source: 0001225208-19-004213 · doc4.xml · derivative · entry 7 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,017 shares Expires 2019-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 27, 2019 Filed Mar 2, 2019 00:37 UTC |
JOHNSON RADY AExecutive Vice President
|
Tax withholdingCommon Stock | 18,538 | $42.31 | $784,342.78 |
DisclosureSEC source: 0001225208-19-004213 · doc4.xml · nonDerivative · entry 5 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,497 F5 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F6 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. Read SEC document |
| February 27, 2019 Filed Mar 2, 2019 00:37 UTC |
JOHNSON RADY AExecutive Vice President
|
Tax withholdingCommon Stock | 10,860 | $42.93 | $466,219.80 |
DisclosureSEC source: 0001225208-19-004213 · doc4.xml · nonDerivative · entry 4 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,035 F4 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document |
| February 27, 2019 Filed Mar 2, 2019 00:37 UTC |
JOHNSON RADY AExecutive Vice President
|
Tax withholdingCommon Stock | 5,622 | $42.93 | $241,352.46 |
DisclosureSEC source: 0001225208-19-004213 · doc4.xml · nonDerivative · entry 3 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,895 F3 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. Read SEC document |
| February 27, 2019 Filed Mar 2, 2019 00:37 UTC |
JOHNSON RADY AExecutive Vice President
|
GrantCommon Stock | 22,176 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-004213 · doc4.xml · nonDerivative · entry 2 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,517 F2 · shares: The reported transaction constitutes the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document |
| February 27, 2019 Filed Mar 2, 2019 00:37 UTC |
JOHNSON RADY AExecutive Vice President
|
Exercise / conversionCommon Stock | 30,017 | $32.23 | $967,447.91 |
DisclosureSEC source: 0001225208-19-004213 · doc4.xml · nonDerivative · entry 1 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,341 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.